American College of Clinical Pharmacy
      Search      Cart
         

Call for Abstracts

All investigators in the field of clinical pharmacy and clinical pharmacology, ACCP members and nonmembers alike, are invited to submit  abstracts to be considered for presentation at the 2017 Annual Meeting in Phoenix, Arizona, October 7-10, 2017. All abstracts accepted for presentation, except for "Encore" and “Research-in-Progress” presentations, will have full-text abstracts published online in Pharmacotherapy. Only the abstract title, authors, and original citation will be published in Pharmacotherapy for “Encore” presentations. All abstracts accepted for presentation will be published full-text in the ACCP Annual Meeting App. Posters from all categories will be distributed across the poster display sessions/days throughout the meeting.

Please read the General Instructions carefully as new requirements have been implemented across all abstract submission categories.

For example, to comply with continuing education requirements all abstract submissions will require a CV and a Conflict of Interest Declaration Statement for the presenting author at the time of submission.

2017 Annual Meeting Abstract Categories


Original Research

Advances in Int'l Clin Pharm Practice, Education, or Training

Systematic Reviews/Meta-Analyses

Residents and Fellows Research in Progress

Clinical Pharmacy Forum

General Instructions

Word Count: All abstract categories have a 300 count word limit.

Original Research: Abstract Deadline: June 15, 2017, Midnight (23:59:59) PDT

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

  • Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
  • Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions. For ACCP's specific evaluation criteria, click here.
  • Descriptions of planned research efforts or preliminary data will not be accepted.
  • To be eligible for Best Poster, Student Best Poster, or Resident/Fellow Best Poster the abstract must fit and be submitted in this category. For specific eligibility criteria, click here.
  • Original research findings presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).
  • A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Original Research category if the previous abstract:
    1. was a descriptive report of planned research only,
    2. described preliminary results only and complete results are now available,
    3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
    4. was presented at an ACCP Chapter or PRN event, or
    5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.

** A copy of the original abstract and the full citation of where/when the research was presented must accompany submission. ACCP reserves the right to determine the extent of difference necessary to substantiate a new Original Research abstract submission.

Systematic Reviews/Meta-Analyses: Abstract Deadline: June 15, 2017, Midnight (23:59:59) PDT

Abstracts must describe a systematic review adhering to the guidelines and definitions established by Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA, http://www.prisma-statement.org/) and include the 12-items published in the PRISMA for Abstracts checklist (http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1001419).

  • Abstracts must be structured with the PRISMA for Abstracts format: Background, methods, results, discussion, and other.
  • Abstracts will be evaluated based on merits of the 12 PRISMA for Abstracts checklist items: Title, objectives, eligibility criteria, information sources, risk of bias, included studies, synthesis of results, description of the effect, strengths and limitations of evidence, interpretation, funding, and registration. For ACCP’s specific evaluation criteria, click here.
  • Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below). 

Case Reports:  Abstract Deadline: June 15, 2017, Midnight (23:59:59) PDT

Abstracts of case reports must update and expand therapeutic insights and possibilities, or generate research hypotheses. While narrative in nature, these abstracts must stress the "evidence" for the authors' conclusions by describing the process followed to understand the findings and possible mechanisms involved in the patient's case, how the patient was evaluated and treated, and a specific description of the outcome.

  • Abstracts must be structured with the section headers:  Introduction, case, discussion, and conclusion.
  • Case report abstracts will be evaluated based on the abstract criteria recommended by the CARE Guidelines (CAse REport Group, http://www.care-statement.org/resources/checklist): uniqueness of report, clinical findings presented, outcomes documented, and “take-away” lessons. For ACCP’s specific evaluation criteria, click here.
  • Abstracts of case reports presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).

Clinical Pharmacy Forum: Abstract Deadline: June 15, 2017, Midnight (23:59:59) PDT

Abstracts must describe the delivery of, justification or documentation for, and impact/significance of innovative clinical pharmacy services implemented. Abstracts that address components of the ACCP Standards of Practice for Clinical Pharmacists (see www.accp.com/standards) and/or describe efforts to develop, advance, or position clinical pharmacists to optimize patient care are encouraged. Abstracts may be descriptive and need not contain an evaluative component. Encore submissions are welcome.

  • Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
  • Descriptions of planned services or programs will not be accepted.
  • Abstracts will be evaluated based on originality of the service or program, adequacy of justification/documentation, adaptability to other settings, and significance to clinical pharmacy. For ACCP’s specific evaluation criteria, click here.
  • Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).

Advances in International Clinical Pharmacy Practice, Education, or Training: Abstract Deadline: June 15, 2017, Midnight (23:59:59) PDT

Abstracts must describe the delivery of, justification or documentation for, and significance of clinical pharmacy practice, education, or training outside of the United States. Abstracts may be descriptive and need not contain an evaluative component.

  • Abstracts must be structured with the section headers of: Service or program, justification/documentation, adaptability, and significance.
  • Abstracts will be evaluated based on the originality of the service or program to the specific setting, adequacy of justification/documentation, adaptability to other settings, and significance to international clinical pharmacy advancement. For ACCP’s specific criteria, click here.
  • Abstracts presented elsewhere, but important to clinical pharmacy, are encouraged as “Encore” submissions (see Encore Presentation details below).

Residents and Fellows Research-in-Progress: Abstract Deadline: July 15, 2017, Midnight (23:59:59) PDT

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

  • The presenting author must be in a post-graduate training program (PGY-1 or PGY-2 residency, Ph.D./Masters graduate degree program, or fellowship training program).
  • Abstracts submitted in the Research-in-Progress category are not eligible for the Resident and Fellow Best Poster competition. *Note: to be eligible for the Best Poster competition, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a resident or fellow.
  • All papers will be assigned to poster format.
  • In-Progress abstracts will be published in the Meeting App, only. 

Student Research-in-Progress: Abstract Deadline: July 15, 2017, Midnight (23:59:59) PDT

Submission guidelines are those of an Original Research abstract except that the research effort is ongoing at the time of abstract submission.

  • The presenting author must be a first professional degree (Pharm.D. or B.S. Pharm.) student.
  • Abstracts submitted in the Research-in-Progress category are not eligible for the Student Best Poster competition. *Note: to be eligible for the Best Poster competitions, the research must meet the criteria for and be submitted under the Original Research category, indicating that it was conducted by a student.
  • All papers will be assigned to poster format.
  • In-Progress abstracts will be published in the Meeting App, only.

Encore Presentation:  Submission and evaluation criteria are those of either the Original Research, Systematic Review/Meta-Analysis, Case Report, or Clinical Pharmacy Forum category, except that the same abstract was presented elsewhere or published in abstract form only prior to this meeting.

  • Abstracts submitted for Encore Presentations must not be modified from the previously presented/published version. This includes the title, authors, and abstract body. The presenting author may change, but they must be an author on the original abstract.
  • The same abstract may not be presented at more than one national ACCP event.
  • The full abstract will be published in the Meeting App, only.
  • Only the abstract title, authors, and original citation will be published in Pharmacotherapy.
  • Encore Presentations will not be eligible for the Best Poster Awards.
  • Submit Encore Presentation abstracts as either Original Research, Systematic Review/Meta-Analysis, Case Report, or Clinical Pharmacy Forum and select "encore" when prompted, providing the original citation, and a copy of the original abstract.

Word Count: All abstract categories have a 300 count word limit.

Abstracts must summarize quantitative or qualitative findings from completed research. Basic, clinical, translational, dissemination/implementation, or educational research are examples of acceptable research. Topics should appeal to a clinical pharmacy audience and may include research in drug metabolism, education/pedagogy, health services, medication safety, patient/population outcomes, pharmacokinetics, pharmacodynamics, pharmacoeconomics, pharmacoepidemiology, pharmacogenomics, pharmacology, or pharmacotherapy. Abstracts reporting in vitro or animal research are welcome.

  • Abstracts must be structured with the section headers of: Introduction, research question or hypothesis, study design, methods, results, and conclusions.
  • Abstracts will be evaluated based on merits of the research question/hypothesis, study design, originality, methods, data analysis, results, and conclusions.
  • Descriptions of planned research efforts or preliminary data will not be accepted.
  • A previously presented abstract may form the basis for a new abstract to be submitted for consideration in the Late-Breaking Original Research category if the previous abstract:
    1. was a descriptive report of planned research only,
    2. described preliminary results only and complete results are now available,
    3. was presented at a student, resident, or fellow conference focused on gaining presentation experience and/or formative feedback,
    4. was presented at an ACCP Chapter or PRN event, or
    5. conclusions have been added/modified based on a new hypothesis and data analysis of the original results database.

Selection Notification:

  • Abstract authors, except "Late-Breakers," will be notified of selection by August 1, 2017
  • Abstract authors will be notified of selection by August 1, 2017
  • Late-Breaker authors will be notified by September 15, 2017